Brought to you by
Flow Forward: Advanced Biomedical Cytometry
Where native-cell integrity becomes clinical insight.
About the event
Minimal sample perturbation assays are relevant because they allow for the study of biological systems in a state that closely mimics their natural in vivo conditions, leading to more accurate and clinically predictive data.
Attend this talk to discover how preserving the native state of immune cells—like Myeloid-Derived Suppressor Cells (MDSCs)—allows for the accurate measurement of their PD-L1 index. We’ll demonstrate how this index directly correlates with poor patient survival in cancer, proving that ultra-precise lab technique is now a decisive factor in selecting successful personalized cancer treatments.
Key Learnings:
Uncover the Critical Technique: Learn how minimal sample perturbation protocols are non-negotiable for accurate flow cytometry, ensuring that fragile immune cell phenotypes and functions—key to therapeutic prediction—are not destroyed during sample preparation.
Master the Prognostic Biomarker: Discover the clinical significance of the PD-L1 index on circulating MDSCs (Myeloid-Derived Suppressor Cells), which serves as a powerful, early predictor of non-response to anti-PD-1/PD-L1 immunotherapy in NSCLC patients.
Who Should Attend:
Immunologists, Oncologists, Clinical Researchers, and Lab Directors seeking to implement state-of-the-art diagnostic tools for improving patient stratification and personalizing immune checkpoint inhibitor therapy.
Dr. Jordi Petriz
Group Leader Scientist
Institut de Recerca Germans Trias i Pujol (IGTP)
Featured Sponsor
